blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3180328

EP3180328 - QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.01.2021
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  14.02.2020
FormerGrant of patent is intended
Status updated on  13.10.2019
FormerExamination is in progress
Status updated on  30.03.2018
FormerRequest for examination was made
Status updated on  19.05.2017
FormerThe international publication has been made
Status updated on  11.03.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Rigel Pharmaceuticals, Inc.
1180 Veterans Boulevard
South San Francisco, CA 94080 / US
[2017/25]
Inventor(s)01 / CARROLL, David
330 Parnussus Avenue
No. 302
San Francisco, CA 94117 / US
02 / SRAN, Arvinder
37623 Central Cove Court
Fremont, CA 94536 / US
03 / SINGH, Rajinder
1832 Hillman Avenue
Belmont, CA 94002 / US
04 / HUANG, Jianing
900 Constitution Drive
Foster City, CA 94404 / US
05 / TSVETKOV, Lyuben
1000 Foster City Boulevard, Apt. 6208
Foster City, CA 94404 / US
06 / ISSAKANI, Sarkiz
2015 Helena Way
Redwood City, CA 94061 / US
07 / PAYAN, Donald
24 Windsor Drive
Hillsborough, CA 94010 / US
08 / SHAW, Simon
1232 19th Street
Unit 10
Oakland, CA 94607 / US
 [2020/12]
Former [2017/25]01 / CARROLL, David
300 Laguna Honda Boulevard, Apt. 204
San Francisco, CA 94116 / US
02 / SRAN, Arvinder
37623 Central Cove Court
Fremont, CA 94536 / US
03 / SINGH, Rajinder
1832 Hillman Avenue
Belmont, CA 94002 / US
04 / HUANG, Jianing
900 Constitution Drive
Foster City, CA 94404 / US
05 / TSVETKOV, Lyuben
1000 Foster City Boulevard, Apt. 6208
Foster City, CA 94404 / US
06 / ISSAKANI, Sarkiz
2015 Helena Way
Redwood City, CA 94061 / US
07 / PAYAN, Donald
24 Windsor Drive
Hillsborough, CA 94010 / US
08 / SHAW, Simon
1232 19th Street
Unit 10
Oakland, CA 94607 / US
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2020/12]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2017/25]Sexton, Jane Helen
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date15753856.214.08.2015
[2017/25]
WO2015US45174
Priority number, dateUS201462037449P14.08.2014         Original published format: US 201462037449 P
[2017/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016025779
Date:18.02.2016
Language:EN
[2016/07]
Type: A1 Application with search report 
No.:EP3180328
Date:21.06.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 18.02.2016 takes the place of the publication of the European patent application.
[2017/25]
Type: B1 Patent specification 
No.:EP3180328
Date:18.03.2020
Language:EN
[2020/12]
Search report(s)International search report - published on:EP18.02.2016
ClassificationIPC:C07D401/14, C07D215/40, C07D401/04, C07D401/12, C07D405/04, C07D409/04, A61K31/4706, A61K31/496, A61K31/5377, A61P35/00
[2017/25]
CPC:
C07D215/40 (EP,US); A61P19/00 (EP); A61P25/00 (EP);
A61P29/00 (EP); A61P35/00 (EP); A61P37/02 (EP);
A61P9/00 (EP); C07D401/04 (EP,US); C07D401/12 (EP,US);
C07D401/14 (EP,US); C07D405/04 (EP,US); C07D409/04 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/25]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:CHINOLINDERIVATE ALS UBIQUITINIERUNG INHIBITOREN[2017/25]
English:QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS[2017/25]
French:DÉRIVÉS DE QUINOLÉINE UTILES EN TANT QU'INHIBITEURS D'UBIQUITINATION[2017/25]
Entry into regional phase10.03.2017National basic fee paid 
10.03.2017Designation fee(s) paid 
10.03.2017Examination fee paid 
Examination procedure10.03.2017Examination requested  [2017/25]
10.03.2017Date on which the examining division has become responsible
09.10.2017Amendment by applicant (claims and/or description)
03.04.2018Despatch of a communication from the examining division (Time limit: M06)
11.10.2018Reply to a communication from the examining division
15.01.2019Despatch of a communication from the examining division (Time limit: M04)
15.05.2019Reply to a communication from the examining division
14.10.2019Communication of intention to grant the patent
10.02.2020Fee for grant paid
10.02.2020Fee for publishing/printing paid
10.02.2020Receipt of the translation of the claim(s)
Opposition(s)21.12.2020No opposition filed within time limit [2021/08]
Fees paidRenewal fee
28.08.2017Renewal fee patent year 03
27.08.2018Renewal fee patent year 04
27.08.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.08.2015
AL18.03.2020
AT18.03.2020
CY18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
MK18.03.2020
MT18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
TR18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
IE14.08.2020
LU14.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
[2022/31]
Former [2022/30]HU14.08.2015
AL18.03.2020
AT18.03.2020
CY18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
MT18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
TR18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
IE14.08.2020
LU14.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
Former [2022/27]HU14.08.2015
AT18.03.2020
CY18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
MT18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
TR18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
IE14.08.2020
LU14.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
Former [2021/37]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
IE14.08.2020
LU14.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
Former [2021/36]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
LU14.08.2020
BE31.08.2020
CH31.08.2020
LI31.08.2020
Former [2021/24]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SI18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
LU14.08.2020
CH31.08.2020
LI31.08.2020
Former [2021/20]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
LU14.08.2020
CH31.08.2020
LI31.08.2020
Former [2021/18]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
MC18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2021/10]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
PL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2021/09]AT18.03.2020
CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
IT18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2021/08]CZ18.03.2020
DK18.03.2020
EE18.03.2020
ES18.03.2020
FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2020/50]CZ18.03.2020
EE18.03.2020
FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2020/49]CZ18.03.2020
FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SK18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2020/48]FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RO18.03.2020
RS18.03.2020
SE18.03.2020
SM18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
PT12.08.2020
Former [2020/47]FI18.03.2020
HR18.03.2020
LT18.03.2020
LV18.03.2020
NL18.03.2020
RS18.03.2020
SE18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
Former [2020/46]FI18.03.2020
HR18.03.2020
LV18.03.2020
NL18.03.2020
RS18.03.2020
SE18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
IS18.07.2020
Former [2020/45]FI18.03.2020
HR18.03.2020
LV18.03.2020
NL18.03.2020
RS18.03.2020
SE18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
Former [2020/39]FI18.03.2020
HR18.03.2020
LV18.03.2020
RS18.03.2020
SE18.03.2020
BG18.06.2020
NO18.06.2020
GR19.06.2020
Former [2020/38]FI18.03.2020
HR18.03.2020
LV18.03.2020
RS18.03.2020
SE18.03.2020
NO18.06.2020
GR19.06.2020
Former [2020/37]FI18.03.2020
HR18.03.2020
LV18.03.2020
RS18.03.2020
SE18.03.2020
NO18.06.2020
Former [2020/35]FI18.03.2020
NO18.06.2020
Cited inInternational search[XY] US2007254894  (KANE JOHN L JR et al.) [X] 1,3,5-8,10,13-16,18,28,29,58-61,63,65,83,89,98,99,102-113,116,117,119,120,122,123 * compound 110 on page 36, compound 109 on page 35 and compound 73 in Table 5 on page 31; paragraphs [0029] , [0034] , [0041] - [0043]; claims 1,6,41 *[Y] 1
 [XY] US2012214803  (BUHR WILM et al.) [X] 1,5-8,10,13-16,18,28,29,58-60,62,65,70,98,99,102,103,105-113,115-117,119,120,122,123 * last two compounds on page 60, 2nd and 3rd compound on page 62, compound 226 on page 25, intermediates 272 and 273 on page 145; paragraphs [0023] , [0614]; claims 1,10,12 *[Y] 1
 [X] WO2008074068  (PRANA BIOTECHNOLOGY LTD et al.) [X] 1,4,5,98 * compounds on pages 13-15 and 57;; claims 8,18,30 *
 [Y] US2005009871  (RAMESH USHA V et al.) [Y] 1 * compound 219 on page 57; paragraph [0019]; claims 1,25,31,36 *
 [Y] WO2012122534  (UNIV COLUMBIA et al.) [Y] 1 * page 14; figures 1-17; claim 1 *
 [Y] WO2013052943  (UNIV MICHGIAN et al.) [Y] 1 * compounds on pages 148 and 149;; claims 1,16,19 *
 [X]   SHRIDHAR BHAT ET AL: "Substituted oxines inhibit endothelial cell proliferation and angiogenesis", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 10, no. 15, 1 January 2012 (2012-01-01), pages 2979, XP055037778, ISSN: 1477-0520, DOI: 10.1039/c2ob06978d [X] 1,5 * compound 55 in Table 2 and in Fig. 2 *

DOI:   http://dx.doi.org/10.1039/c2ob06978d
 [X]   SUNG KEON NAMGOONG ET AL: "Synthesis of the Quinoline-Linked Triazolopyrimidine Analogues and Their Interactions with the Recombinant Tobacco Acetolactate Synthase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 258, no. 3, 1 May 1999 (1999-05-01), pages 797 - 801, XP055214707, ISSN: 0006-291X, DOI: 10.1006/bbrc.1999.0708 [X] 1,4 * compounds 1A, 1B, 2A, 2B, 3A, 3B and 5B in Fig. 3 *

DOI:   http://dx.doi.org/10.1006/bbrc.1999.0708
 [X]   DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 July 2004 (2004-07-15), XP002744796, Database accession no. 710307-72-5 [X] 1,4,5 * compounds cas rn: 710307-72-5 and 710307-74-7 *
 [X]   DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 December 2007 (2007-12-18), XP002744797, Database accession no. 958585-17-6 [X] 1,4 * compounds cas rn: 958585-17-6, 958580-29-5 and 958565-04-3 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.